Articles tagged with Melanoma
A genetic mutation known as Id1 may help detect melanoma early, when it's still curable. High levels of Id1 are found only in the first stages of melanoma, making it a potential diagnostic marker.
Researchers found that survival rates for primary eye cancer treatments are essentially the same, with a five-year survival rate of 82% for both radiation therapy and eye removal. The study's findings expand the capability of doctors to provide accurate diagnoses and state-of-the-art treatments.
A recent study by Ohio State University found that survival rates are similar for patients with choroidal melanoma who undergo radiation therapy or have their affected eye removed. The study, which involved 1,317 patients, showed that both treatment options result in high five-year survival rates.
Researchers found that malignant melanomas often lose the protein Apaf-1, leading to resistance to chemotherapy drug adriamycin. Restoring Apaf-1 in melanoma cells rescues their ability to kill themselves in response to adriamycin.
A definitive study led by John Kirkwood at the University of Pittsburgh Cancer Institute found that high-dose interferon alfa 2b extends both overall survival and relapse-free survival in surgically treated high-risk melanoma patients. This regimen significantly outperforms a comparison vaccine, GMK, in terms of survival impact.
Researchers found a genetic signature that divides patients with advanced melanoma into subgroups, offering clues to the disease's biology. This discovery could lead to more accurate prognosis and tailored therapies.
Researchers at UCSD develop a new drug-combination therapy using tamoxifen and cisplatin, significantly improving survival rates for patients with metastatic melanoma. The treatment results in a 62% reduction in tumor recurrence after five years.
A Phase III study found that a combination of histamine dihydrochloride and lower doses of interleukin-2 improved overall survival, increased survival rates at 12, 18, and 24 months, and reduced time-to-disease-progression compared to IL-2 alone. The treatment was well-tolerated and had substantially less toxicity.
The study confirms that M-Vax increases the survival rate of patients with advanced Stage III melanoma, even after disease recurrence. Patients who developed an immune response against their melanoma had a far better outcome, with a five-year survival rate of 65%.
A custom-made vaccine created from a patient's own cancer tumor cells has proven effective in prolonging the survival of patients with malignant melanoma. The vaccine resulted in a 47% five-year survival rate among 214 patients with disease spread, outperforming standard treatment.
Researchers at the Mayo Clinic found that an experimental diode laser treatment controlled cancer growth in all but one patient with melanoma in the eye. No recurrences were noted in the remaining patients during follow-up periods.
The Wistar Institute has received a five-year grant from the National Cancer Institute to develop new diagnostic tools and treatments for metastatic melanoma. The goal of this project is to improve patient outcomes by understanding the underlying molecular events that contribute to the development and progression of the disease.
A UCSF study reports that melanoma patients with cancer spread to their sentinel lymph nodes have a greater chance of experiencing disease recurrence and mortality. The study found that patients with negative SLN biopsies had lower rates of disease recurrence and mortality.
Jefferson researchers report progress in using a vaccinia-based vaccine to treat advanced melanoma, with two patients achieving complete remission. The vaccine works by boosting the immune system with granulocyte macrophage colony stimulating factor (GM-CSF), but more research is needed to enhance the treatment.
Researchers at The Wistar Institute have discovered two genes, Alphav and Beta3, that play a crucial role in melanoma development. These findings suggest that blocking the activity of the vitronectin receptor could be an effective way to prevent cancer progression.
A University of Wisconsin-Madison research team has developed a gene therapy vaccine that helps the animal's immune system recognize and attack cancer cells. The vaccine was tested on 16 dogs with advanced stages of melanoma and showed promise, with some animals living longer and tumor shrinkage in about 20 percent of cases.
A large population-based study found no relationship between sunscreen use and melanoma risk, as people's reports of sunburn histories were inconsistent. Instead, genetic characteristics such as moles and pigmentary phenotype are major determinants of melanoma risk.
Mohs surgery has shown promise in preventing melanoma recurrence, particularly in patients with lentigo-maligna tumors. The technique's precision and ability to check surgical margins may provide a better chance of getting rid of tumors and preventing recurrences while conserving tissue.
Researchers have discovered that GM-CSF, a cytokine produced by melanoma tumors, can stimulate the immune system to attack and eliminate tumor cells. Delivering GM-CSF directly to tumors may lead to effective treatment of advanced melanoma cases.
Researchers infected mouse melanocytes with a retrovirus and observed transformed cells behaving like melanoma cells. The study aims to understand the molecular mechanisms underlying melanoma in people by identifying cellular genes disturbed by the virus.
Researchers at Penn State have discovered a new gene called KiSS-1 that suppresses the metastasis of melanoma in laboratory mice. The gene, located on chromosome 1, reduces the spread of melanoma by at least 50 percent of the time and may be the most potent gene to block or suppress metastasis in human cancer.